• June 3-6, 2024
  • San Diego Convention Center, California



Yifan Pharmaceutical

Wednesday, June 05, 2024
Company Presentation
Multiple Therapeutics
Company Presentation Theater 2
Evive Biotech, a subsidiary of Yifan Pharmaceutical, is a global biopharmaceutical company devoted to developing a portfolio of novel biological therapies for patients worldwide. We leverage our FC fusion protein technology platforms to advance a series of innovative drug candidates for oncology, inflammatory and metabolic diseases. Founded in 2004, we currently have operations in the US, EU, Singapore, and China. Evive's Ryzneuta (G-CSF and IgG2 FC fusion protein, aka F-627) has recently been approved in China, US and EU for treating cancer drug induced neutropenia. In the pipeline, F-652 (IL-22 and IgG2 FC fusion protein) has completed phase I-II clinical studies in acute on chronic liver failure, alcoholic hepatitis, and acute graft vs host disease, and shown good safety, efficacy and PK/PD profiles.
Yifan Pharmaceutical
Company Website: https://www.evivebiotech.com/en/index/index
Lead Product in Development: IL-22:IgG2FC
Number Of Unlicensed Products (For Which You Are Seeking Partners): 5

Company HQ City


Company HQ State


Company HQ Country

United States

CEO/Top Company Official

Simon Li, MD/PhD

Development Phase of Primary Product

Phase II
Primary Speaker
Simon Li, MD
CEO/CMO of Evive Biotech and Vice President
Yifan Pharmaceutical
Back to Session List

white squarewhite


Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.